C=o Other Than As Ketone Or Aldehyde Patents (Class 514/527)
-
Patent number: 9724320Abstract: The present invention relates to a composition for preventing or treating renal fibrosis comprising dimethylfumarate (DMF) as an active ingredient. The DMF according to the present invention has an excellent effect of reducing renal fibrosis by activating Nrf2 to inhibit TGF-?/Smad signaling, and thus is useful for preventing or treating renal fibrosis.Type: GrantFiled: February 20, 2013Date of Patent: August 8, 2017Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATIONInventors: In Kyu Lee, Keun Gyu Park, Chang Joo Oh, Han Jong Kim, Joon-Young Kim
-
Patent number: 9677978Abstract: A fixative solution, suitable for fixation of biological materials such as human or veterinary biological tissues, cells, organs and secretions as well as bacteria, viruses, yeasts, parasites and biotech products such as embalming articles. The fixative solution is not a dangerous product according to European standards, and it contains low concentration of aldehydes or heavy metals, rendering a product that cannot be considered dangerous. Even so, biological samples can be optimally preserved and fixed with this solution.Type: GrantFiled: May 2, 2011Date of Patent: June 13, 2017Inventor: Roberto Gerigk
-
Patent number: 9636319Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.Type: GrantFiled: December 21, 2016Date of Patent: May 2, 2017Assignee: BANNER LIFE SCIENCES LLCInventors: Jason M. Vaughn, Justin R. Hughey, Tanesha Roberts, Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
-
Patent number: 8603451Abstract: The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field.Type: GrantFiled: May 22, 2012Date of Patent: December 10, 2013Assignee: Adhezion Biomedical, LLCInventors: Sheng Zhang, Rafael Ruiz
-
Publication number: 20130178426Abstract: The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion.Type: ApplicationFiled: August 10, 2011Publication date: July 11, 2013Applicant: Terumo Kabushiki KaishaInventors: Takao Anzai, Atsuhiko Nogawa, Yuichi Tada
-
Patent number: 8293838Abstract: A stable and sterile adhesive composition with a controlled level of high viscosity is disclosed in the present invention. Adhesive compositions with different ranges of viscosity could be prepared by heating the adhesive monomer composition at mild temperature in the presence of pluronic polymer. The viscosity of the adhesive composition is able to be controlled to any desired level. A method of stabilizing the adhesive composition with a desired level of high viscosity is provided by using the combination of free radical and acid stabilizers. Methods for packaging, sterilizing and applying the adhesive in the medical field are also provided.Type: GrantFiled: June 20, 2008Date of Patent: October 23, 2012Assignee: Adhezion Biomedical, LLCInventors: Sheng Zhang, Rafael Ruiz
-
Patent number: 8198344Abstract: The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field.Type: GrantFiled: June 20, 2008Date of Patent: June 12, 2012Assignee: Adhezion Biomedical, LLCInventors: Sheng Zhang, Rafael Ruiz
-
Publication number: 20120029071Abstract: The invention provides compositions and methods featuring Nrf2 activators for treating or preventing radiation-associated tissue damage.Type: ApplicationFiled: November 23, 2009Publication date: February 2, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Shyam Biswal, Rajesh K. Thimmulappa
-
Patent number: 7872152Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: GrantFiled: August 9, 2007Date of Patent: January 18, 2011Assignee: The Brigham and Women's Hospital, Inc.Inventors: Charles N. Serhan, Bruce D. Levy
-
Patent number: 7862800Abstract: This invention relates to sterilized cyanoacrylate adhesive compositions with x-ray imagining capabilities, methods of making such compositions, and methods of using such compositions.Type: GrantFiled: January 10, 2006Date of Patent: January 4, 2011Assignee: Henkel AG & Co. KGaAInventors: Kenneth N. Broadley, Noeleen B. Swords, Clare P. Grealis
-
Publication number: 20100256230Abstract: The invention relates to new butane acid derivatives comprising a cyanide group, pharmaceutical compositions containing said butane acid derivatives and the use of said butane acid derivatives in the production of pharmaceutical compositions for treating various illnesses.Type: ApplicationFiled: October 5, 2009Publication date: October 7, 2010Applicant: SCHEBO BIOTECH AGInventors: Erich Eigenbrodt, Stefan Mullner, Sybille Mazurek, Hugo Fasold
-
Patent number: 7598292Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.Type: GrantFiled: September 16, 2004Date of Patent: October 6, 2009Assignee: Janssen Pharmaceutica, N.V.Inventors: Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
-
Patent number: 7351427Abstract: Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and/or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.Type: GrantFiled: April 30, 2003Date of Patent: April 1, 2008Assignee: Busulipo ABInventors: Zuzana Hassan, Moustapha Hassan
-
Patent number: 7183318Abstract: The invention concerns compounds of formula (1): R-A-R? wherein: A is as defined in the description; R represent a group (V), (VI), (VII), or (VIII), where E, Q, R1, R2, R3, v and R4 are as defined in the description; R? represents a —(CH2)t—R5 group wherein t and R5 are as defined in the description, and medicaments containing the sameType: GrantFiled: June 16, 2003Date of Patent: February 27, 2007Assignee: Les Laboratoires ServierInventors: Daniel Lesieur, Frederique Klupsch, Gerald Guillaumet, Marie-Claude Viaud, Michel Langlois, Caroline Bennejean, Pierre Renard, Philippe Delagrange
-
Patent number: 7019031Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.Type: GrantFiled: October 23, 2001Date of Patent: March 28, 2006Assignee: The Arizona Disease Control Research CommissionInventors: Seth D. Rose, Scott R. Lefler, Steven R. Ottersberg, Ann Y. Kim, Karl J. Okolotowicz, Rosemarie F. Hartman
-
Patent number: 6995180Abstract: A compound of the formula I: wherein R1, R2, R3 and R4 are as defined herein. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.Type: GrantFiled: October 21, 2003Date of Patent: February 7, 2006Assignee: Bristol Myers Squibb CompanyInventors: David R. Magnin, Lawrence G. Hamann
-
Patent number: 6903052Abstract: The invention concerns the use of certain compounds related to fatty acids to control nematodes that infest plants or the situs of plants. Nematodes that parasitize animals can also be controlled using the methods and composition of this invention. Certain of the useful compounds are fatty acid esters that are predicted inhibitors of nematode delta-12 fatty acid desaturases and can be, for example, from C16 to C20 in length.Type: GrantFiled: July 1, 2002Date of Patent: June 7, 2005Assignee: Divergence, Inc.Inventors: Deryck J. Williams, Andrew P. Kloek, Michelle Coutu Hresko
-
Publication number: 20040259946Abstract: In one aspect, the invention provides a process for the preparation of compounds of Formula I 1Type: ApplicationFiled: August 12, 2004Publication date: December 23, 2004Inventors: Tom Thomas Puthiaparampil, Acharya Poornaprajna, Chandrashekar Aswathanarayanappa, Madhavan Sridharan, Sambasivam Ganesh
-
Publication number: 20040259919Abstract: A compound of the formula I: 1Type: ApplicationFiled: October 21, 2003Publication date: December 23, 2004Inventors: David R. Magnin, Lawrence G. Hamann
-
Publication number: 20040054001Abstract: The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives for preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB.Type: ApplicationFiled: July 10, 2003Publication date: March 18, 2004Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel, Peter Petzelbauer
-
Publication number: 20030176402Abstract: The invention concerns the use of certain compounds related to fatty acids to control nematodes that infest plants or the situs of plants. Nematodes that parasitize animals can also be controlled using the methods and composition of this invention. Certain of the useful compounds are fatty acid esters that are predicted inhibitors of nematode delta-12 fatty acid desaturases and can be, for example, from C16 to C20 in length.Type: ApplicationFiled: July 1, 2002Publication date: September 18, 2003Inventors: Deryck J. Williams, Andrew P. Kloek, Michelle Coutu Hresko
-
Patent number: 6579916Abstract: Disclosed are methods for sterilizing cyanoacrylate prepolymer compositions under visible light irradiation conditions wherein the prepolymer remains in polymerizable form after sterilization.Type: GrantFiled: November 21, 2001Date of Patent: June 17, 2003Assignee: MedLogic Global CorporationInventors: Ian N. Askill, Shane C. Karnik, Richard L. Norton
-
Patent number: 6545043Abstract: A method for suppressing target pests, comprising exposing the pests to an effective biopesticidal amount of a composition, the composition comprising a carrier and a purified glucosinolate breakdown product having a hydroxyl group attached, wherein a starting material for the purified glucosinolate breakdown product is isolated from a crambe plant or mustard plant, further wherein the target pests are plants, fungi, bacteria or root knot nematodes is disclosed. Methods for suppressing target pests without limitation as to the starting materials are also disclosed wherein the pests are exposed to an effective biopesticidal amount of a composition comprising a carrier and either an analog or a derivative of a purified glucosinolate breakdown product having a hydroxyl group attached.Type: GrantFiled: May 31, 2000Date of Patent: April 8, 2003Assignee: Iowa State University Research Foundation, Inc.Inventors: Joel R. Coats, Christopher J. Peterson, Rong Tsao, Aimee L. Eggler, Gregory L. Tylka
-
Patent number: 6538026Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: GrantFiled: May 23, 2000Date of Patent: March 25, 2003Assignee: Provasis Therapeutics, Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6512023Abstract: An adhesive composition includes a polymerizable adhesive monomer, at least one vapor phase stabilizer, and at least one liquid phase stabilizer. The combination of at least one vapor phase stabilizer and at least one liquid phase stabilizer provides superior stabilization and shelf-life for the monomer composition. The stabilized adhesive composition provides superior performance and shelf-life and can be sterilized without significant polymerization of the monomer.Type: GrantFiled: June 18, 1998Date of Patent: January 28, 2003Assignee: Closure Medical CorporationInventors: Bernard Malofsky, Andrés Rivera, Gabriela Rueda
-
Publication number: 20030018072Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.Type: ApplicationFiled: July 17, 2002Publication date: January 23, 2003Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
-
Patent number: 6476069Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.Type: GrantFiled: January 29, 1999Date of Patent: November 5, 2002Assignee: Provasis Therapeutics Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6476070Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: GrantFiled: February 2, 2000Date of Patent: November 5, 2002Assignee: Provasis Therapeutics Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6303653Abstract: In accordance with the present invention, there are provided therapeutically effective compounds comprising an amphipathic carboxylate of the formula R—COOH, or a salt or an ester or amide of such compound, where R designates a saturated or unsaturated alkyl chain of 10-24 carbon atoms, one or more of which may be replaced by heteroatoms, where one or more of said carbon or heteroatom chain members optionally forms part of a ring, and where said chain is optionally substituted by a hydrocarbyl radical, heterocyclyl radical, lower alkoxy, hydroxyl-substituted lower alkyl, hydroxyl, carboxyl, halogen, phenyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted phenyl, C3-C7 cycloalkyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkinyl)-substituted C3-C7 cycloalkyl wherein said amphipathic carboxylate is capable of being endogenously converted to its respective coenzyme A thioester.Type: GrantFiled: June 25, 1998Date of Patent: October 16, 2001Assignee: Yissum Research Development Company of The Hebrew University of JerusalemInventor: Jacob Bar-Tana
-
Patent number: 6245804Abstract: This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.Type: GrantFiled: May 29, 1998Date of Patent: June 12, 2001Assignee: Schering AktiengesellschaftInventors: Manfred Lehmann, Klaus Schoellkopf, Peter Strehlke, Nikolaus Heinrich, Karl-Heinrich Fritzemeier, Rolf Krattenmacher, Hans-Peter Muhn
-
Patent number: 6207705Abstract: The present invention provides novel biopesticides which can replace commercial pesticides and biopesticides which have been banned, restricted, or are being phased out, including, but not limited to chloropicrin, dichlorvos and methyl bromide. Many of the biopesticides of the present invention are excellent fumigants, possessing quick action and volatility, while posing less risk than currently used pesticides to humans and the environment. The biopesticides of the present invention are natural and closely-related synthetic derivatives or analogs related to two classes of natural compounds, namely glucosinolates and monoterpenoids.Type: GrantFiled: March 21, 1997Date of Patent: March 27, 2001Assignee: Iowa State University Research Foundation, Inc.Inventors: Joel R. Coats, Christopher J. Peterson, Rong Tsao, Aimee L. Eggler, Gregory L. Tylka
-
Patent number: 6143805Abstract: A method for sterilizing a liquid adhesive composition includes subjecting the composition to electron beam irradiation while it is enclosed in a container.Type: GrantFiled: February 18, 1998Date of Patent: November 7, 2000Assignee: Closure Medical CorporationInventors: Timothy Hickey, Ubonwan A. Stewart
-
Patent number: 6071888Abstract: The present invention is directed to compositions containing beta-alanine which are useful for treating cancer. The composition preferably comprises a ribose compound, L-beta-alanine, ascorbic acid, and nicotinic acid. The present invention is particularly directed to a composition useful for treating melanoma, and a method for treating melanoma with the composition.Type: GrantFiled: January 22, 1997Date of Patent: June 6, 2000Assignee: Aliatros Medical, a.s.Inventors: Blanka Rihova, Yveta Germano, Olga Kufudaki, deceased
-
Patent number: 6037366Abstract: A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.Type: GrantFiled: September 11, 1998Date of Patent: March 14, 2000Assignee: Prohold Medical Technologies, Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 5998472Abstract: Disclosed are mixed alkyl cyanoacrylate compositions which are specifically formulated for topical application onto intact or broken human skin, preferably without the addition of a plasticizing agent to the composition.Type: GrantFiled: October 9, 1998Date of Patent: December 7, 1999Assignee: MedLogic Global CorporationInventors: Thomas Jay Berger, Carlos Roberto Morales, Richard J. Greff, Ian N. Askill
-
Patent number: 5957877Abstract: Disclosed are methods for draping a surgical site prior to surgery. Specifically, the methods of this invention involve the in situ formation of a cyanoacrylate polymeric drape on the skin surface of a patient peripheral to the surgical site. Surgery is then conducted at the surgical site.Type: GrantFiled: November 3, 1997Date of Patent: September 28, 1999Assignee: MedLogic Global CorporationInventors: Ian N. Askill, Michael M. Byram, Richard J. Greff, Richard T. Vanryne
-
Patent number: 5811091Abstract: Disclosed are cyanoacrylate compositions comprising a compatible antimicrobial agent and, in particular, a compatible iodine containing antimicrobial agent. These compositions provide for in situ formation of an antimicrobial polymeric cyanoacrylate film on mammalian skin.Type: GrantFiled: June 6, 1997Date of Patent: September 22, 1998Assignee: Medlogic Global CorporationInventors: Richard J. Greff, Michael M. Byram
-
Patent number: 5753699Abstract: Antimicrobial cyanoacrylate compositions are applied to non-suturable, superficial wound surfaces. In situ polymerization of the cyanoacrylate ester provides for a polymeric film over the wound which promotes wound healing and retards infection of the wound.Type: GrantFiled: October 9, 1997Date of Patent: May 19, 1998Assignee: MedLogic Global CorporationInventors: Richard J. Greff, Michael M. Byram
-
Patent number: 5684042Abstract: Disclosed are cyanoacrylate compositions comprising a compatible antimicrobial agent and, in particular, a compatible iodine containing antimicrobial agent. These compositions provide for in situ formation of an antimicrobial polymeric cyanoacrylate film on mammalian skin.Type: GrantFiled: January 10, 1997Date of Patent: November 4, 1997Assignee: Medlogic Global CorporationInventors: Richard J. Greff, Michael M. Byram
-
Patent number: 5530037Abstract: A curable cyanoacrylate adhesive composition intended for medical and/or veterinary uses is sterilized in liquid form by gamma irradiation. The composition comprisesa) a cyanoacrylate monomerb) a combination of an anionic stabilizer and a free-radical stabilizer in amounts effective to stabilize the composition during irradiation and to stabilize the sterilized composition during storage prior to cure, wherein the free radical stabilizer is a selected phenolic antioxidant (but not including hydroquinone).The preferred free radical stabilizer is butylated hydroxyanisole. After irradiation the cyanoacrylate monomer is substantially ungelled.Type: GrantFiled: December 21, 1994Date of Patent: June 25, 1996Assignee: Loctite (Ireland) LimitedInventors: Patrick F. McDonnell, Robert J. Lambert
-
Patent number: 5358963Abstract: Synergistic compositions for inhibiting microbial growth contain synergistic mixtures including 2-(2-bromo-2-nitroethenyl)furan ("BNEF") and a compound selected from the group consisting of beta-nitrostyrene ("NS"), beta-bromo-beta-nitrostyrene ("BNS"), methylchloro/isothiazolone ("IZN"), methylenebisthiocyanate ("MBT"), 2,2-dibromo-3-nitrilopropionamide ("DBNPA"), 2-bromo-2-bromomethyl-glutaronitrile ("BBMGN"), alkyldimethylbenzylammonium chloride ("ADBAC"), and beta-nitrovinyl furan ("NVF"). The synergistic compositions are effective against a wide spectrum of bacteria, algae and fungi. An antimicrobial composition comprising the synergistic mixture and a carrier is also disclosed.Type: GrantFiled: June 11, 1993Date of Patent: October 25, 1994Assignee: Great Lakes Chemical CorporationInventors: William F. McCoy, Geoffrey A. Brown
-
Patent number: 5302592Abstract: Use as microbicides of thioacryloyl compounds of the formula ##STR1## Compounds and compositions are also disclosed.Type: GrantFiled: August 16, 1993Date of Patent: April 12, 1994Assignee: Rohm and Haas CompanyInventors: Peter Osei-Gyimah, Samuel E. Sherba, Raj J. Mehta, Barry C. Lange, Rhoda W. Joseph
-
Patent number: 4797418Abstract: A one step process for the preparation of certain cyanomethyl carboxylates is disclosed which comprises reacting an appropriate acyl compound with a water soluble metal cyanide such as sodium cyanide or potassium cyanide and an aldehyde such as formaldehyde, acetaldehye, or benzaldehyde. Also disclosed is a method for inhibiting bacteria by contacting said bacteria or habitat thereof with an effective amount of an antibacterial cyanomethyl carboxylate.Type: GrantFiled: August 12, 1986Date of Patent: January 10, 1989Assignee: The Dow Chemical CompanyInventor: Andrew T. Au
-
Patent number: 4689344Abstract: A novel class of compounds has been found to be effective in blocking cholesterol and neutral lipid synthesis in-vivo without adversely affecting energy metabolism, useful for the treatment of obesity, hyperlipidemia and maturity-onset diabetes. The active compounds have the general formula ##STR1## or in-vivo hydrolyzable functional derivatives of the carboxylic groups thereof,whereinR.sub.1 and R.sub.2 each independently represents an unsubstituted or substituted hydrocarbyl or hetercyclyl radical;X and Y each independently represents hydrogen, optionally substituted lower alkyl, halogen, cyano, carboxy, lower alkoxycarbonyl or carbamoyl; andQ represents a diradical consisting of a linear chain of 8 to 14 carbon atoms, one or more of which may be replaced by heteroatoms, said chain being optionally substituted by inert substituents and one or more of said carbon or heteratom chain members optionally forming part of a ring structure.Type: GrantFiled: June 22, 1984Date of Patent: August 25, 1987Assignee: Epis S.A.Inventor: Jacob Bar-Tana
-
Patent number: RE39150Abstract: A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.Type: GrantFiled: March 30, 2001Date of Patent: June 27, 2006Assignee: Prohold Technologies, Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: RE33885Abstract: Polyol fatty acid polyesters having at least four fatty acid ester groups are fortified with fat-soluble vitamins and used in pharmaceutical compositions for treating and/or preventing hypercholesterolemia in animals, especially humans, and in low-calorie foods.Type: GrantFiled: September 29, 1989Date of Patent: April 14, 1992Assignee: The Procter & Gamble CompanyInventor: Fred H. Mattson
-
Patent number: RE42377Abstract: A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.Type: GrantFiled: July 12, 2007Date of Patent: May 17, 2011Assignees: Stryker Corporation, Stryker NV Operations LimitedInventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox